Fulzerasib vs Garsorasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
Fulzerasib · Dupert
Marketed by Innovent Biologics under a licence from GenFleet Therapeutics
NCT05756153 · Phase 1/2 · completed
KROCUS was a single-arm, open-label Phase 1b/2 trial of fulzerasib plus cetuximab in previously untreated KRAS G12C-mutated non-small-cell lung cancer, with 47 patients treated at 30 centres. The Phase 2 primary endpoint was the investigator-assessed objective response rate, and the confirmed rate was 69% (90% CI 56 to 80). With no comparator arm and no formal success threshold reported, no result can be called met or missed. Treatment-related adverse events occurred in 87% of patients, grade 3 in 15%, with no grade 4 or 5 events. The figures come from the final peer-reviewed report (Gregorc et al., Lancet Oncol 2026).
Single-arm response rate with no comparator and no formal statistical threshold.
Next expected readout: March 2027 · NCT07492342 (registry estimate)
Reported efficacy
Phase Ib: adverse events (28 days); Phase II: objective response rate (up to 1 year after last patient in): Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. (not_applicable)
Result source: NCT05756153
Garsorasib · Anfangning
Marketed by Sino Biopharmaceutical and partners
NCT05383898 · Phase 1/2 · completed
The study was a non-randomized, open-label, single-arm trial with no placebo or active comparator, despite enrolling 225 participants. Its primary outcomes included safety measures and overall response rate. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07472478 (registry estimate)
Reported efficacy
Subject incidence of Dose-limiting toxicities (DLT) (through out the DLT period, approximately 21 days); Number of subjects participants with adverse events (Through study completion, approximately 3 years); antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation (Through study completion, approximately 3 years): IRC-confirmed ORR 50% (61 of 123 patients; 95% CI 41-59) (not_applicable)
Result source: NCT05383898
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fulzerasib | Garsorasib |
|---|---|---|
| PFS, median | —Trial running · NCT07601048 | —Trial running · NCT06300177 |
| OS, median | —Trial running · NCT07601048 | —Trial running · NCT06300177 |
| ORR | —Trial running · NCT07601048 | —Trial running · NCT06300177 |
| Duration of response, median | —Trial running · NCT07601048 | —Trial running · NCT06300177 |
PFS, median
- Fulzerasib
- —Trial running · NCT07601048
- Garsorasib
- —Trial running · NCT06300177
OS, median
- Fulzerasib
- —Trial running · NCT07601048
- Garsorasib
- —Trial running · NCT06300177
ORR
- Fulzerasib
- —Trial running · NCT07601048
- Garsorasib
- —Trial running · NCT06300177
Duration of response, median
- Fulzerasib
- —Trial running · NCT07601048
- Garsorasib
- —Trial running · NCT06300177
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulzerasib's landscape · Garsorasib's landscape